KEY POINTS: Worldwide spending on cancer medicines reached $100 billion in 2014, an increase of 10.3 percent from 2013 and up from $75 billion five years earlier, according to IMS Health’s Global Oncology Trend Report. Drugmakers worried about a backlash over soaring drug prices are increasingly talking with insurers ahead of time about paying for new therapies that could cost six figures a year. 14 drugs cost the federal government and Medicare beneficiaries more than $1 billion each, accounting for nearly a quarter of Medicare prescription drug spending in 2013.
Patients who adhere to their medication regi- mens enjoy better health outcomes and make less use of urgent care and inpatient hospital services, compared to patients with similar medi- cal conditions who are not adherent. Yet average medication compliance rates in developed countries of just 50 percent. With so many drugs coming off patent is it time for pharma to really tackle adherence ?
POST SUMMARY: According to the Dallas Morning News, five years ago, cancer treatment accounted for just $157 billion of the nation’s annual $2.6 trillion health bill. Propelled by new drugs and an aging population, however, cancer spending is rising quickly. A forecast from the National Cancer Institute said spending could hit $207 billion by the end of the decade.
POST SUMMARY: Biosimilars are possible thanks to the Affordable Care Act and the law’s promise to bring cheaper versions of expensive biotech drugs to the U.S. market. The biosimilar of Neupogen will save the U.S. health system more than $5.5 billion over the next decade, assuming a “conservative discount of 30 percent off the current brand price,” Express Scripts said
POST SUMMARY: CVS, the nation’s biggest health-related company with nearly $140 billion in annual sales , says this new strata of cholesterol drugs, believed to be a cut above previous medications, would severely strain the healthcare system if prescribed to all the 15 million Americans who could benefit from the drugs.